A Phase 1, Subject-and Investigator blinded, Sponsor unblinded, Placebo-controlled, Randomized, 2 part, Sequential, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DS 1501a in Healthy Young Subjects and Healthy Postmenopausal Women.